VEGFD and wet macular degeneration: Indeed, a suitable biologic, the VEGF-C/VEGF-D trap OPT-302, has recently been fast-tracked by the U.S. Food and Drug Administration (FDA) for the treatment of wet AMD, and clinical trials studying combination treatments of OPT-302 with anti-VEGF-A agents are ongoing [50].